Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128167 | 0.85 | CYP1A1 (0.56) | CYP1A2CYP1A1CYP1B1ALDH1A1MEN1 | |
| SCHEMBL11747282 | 0.85 | GRIN2D (0.73) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL2009040 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL2009041 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL2316541 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL2314671 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL8237102 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL30481109 | 0.81 | GRIN2D (0.64) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL13044403 | 0.80 | MAPT (0.62) | CYP1A2CYP1A1CYP1B1GRIN2DGRIN3B | |
| SCHEMBL14396725 | 0.80 | TRIM24 (0.61) | CYP1A2CYP1A1CYP1B1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | CYP1A2 303/4885CYP1A1 450/4885CYP1B1 716/4885 |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | IL4, IL2, TH | CYP1A2 352/4885CYP1A1 497/4885CYP1B1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.